Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gastrointestinal 1

Conditions

Mesothelioma, Malignant 1Lung Neoplasms 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 10belinostat 2Plicamycin 2Decitabine 2Celecoxib 2tocilizumab 1spartalizumab 1obinutuzumab 1naptumomab estafenatox 1epacadostat 1entinostat 1durvalumab 1alvocidib 1Tetrahydrouridine 1Tablets 1Surgical Procedures, Operative 1Quality of Life 1Polymerase Chain Reaction 1Patient Reported Outcome Measures 1Nivolumab 1Molecular Diagnostic Techniques 1Microarray Analysis 1Levoleucovorin 1Leucovorin 1Ipilimumab 1Interleukin-2 1Immunotherapy, Adoptive 1Immunotherapy 1Immunoenzyme Techniques 1Gene Expression Profiling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophageal Neoplasms × Tetrahydrouridine × Other solid neoplasm × Clear all
NCT03233724 2023-05-31

Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
9 enrolled 14 charts
GastrointestinalOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡